PTC Therapeutics, Inc. (PTCT) Stock Price & How to Invest
Last updated July 2026
Short answer
PTC Therapeutics (PTCT) is a commercial-stage rare-disease biopharma pivoting from legacy Duchenne drugs toward its fast-growing PKU treatment Sephience, so investing in it is a bet that new-product momentum and a deep neurology pipeline can offset the erosion of its older franchises.
PTCT stock price
As of 2026-07-24, PTC Therapeutics, Inc. (PTCT) last closed at $76.82, up 71.7% over the past year. Over the past 52 weeks it has traded between $43.30 and $89.55.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or PTC Therapeutics, Inc.'s investor relations page. Walnut is informational, not investment advice.
What does PTC Therapeutics, Inc. (PTCT) do?
PTC Therapeutics is a New Jersey-based biopharmaceutical company focused on rare and neurological diseases. It sells a portfolio of approved medicines including Sephience (sepiapterin) for phenylketonuria (PKU), Translarna (ataluren) and Emflaza (deflazacort) for Duchenne muscular dystrophy, and Kebilidi, a gene therapy for AADC deficiency. It also earns royalties on Evrysdi (risdiplam), the Roche/Genentech spinal muscular atrophy drug that PTC helped discover, and runs a pipeline led by votoplam, a splicing modifier partnered with Novartis for Huntington's disease.
The investment picture is a classic rare-disease transition story. Total revenue reached roughly $272 million in Q1 2026 (up about 44% year over year), and management raised full-year 2026 product-revenue guidance to $750-$850 million on the strength of the Sephience launch. At the same time, the company carries a stretched balance sheet from monetizing future royalties and faces uncertainty around its European Translarna franchise. The bull case rests on Sephience becoming a global PKU standard and on late-stage neurology readouts; the bear case is that legacy erosion and pipeline risk outweigh the new growth.
What's driving PTC Therapeutics, Inc. (PTCT)?
1. Sephience (PKU) launch ramp
Sephience is the clear growth engine, contributing roughly $125 million in Q1 2026 with about 36% quarter-over-quarter growth. Management is expanding the launch across the US, Europe, and additional markets such as Japan and Brazil, targeting 20-30 countries. Continued adoption in the underserved PKU population is the single biggest driver of the raised 2026 guidance.
2. Evrysdi royalty and cash generation
PTC earns royalties on Roche's Evrysdi, a leading oral SMA therapy, which delivered about $47 million in Q1 2026 royalty revenue. The company monetized a portion of these royalties (including a late-2025 sale to Royalty Pharma) to fund operations, trading future high-margin cash flow for near-term liquidity of roughly $1.9 billion in cash and securities.
3. Votoplam neurology pipeline
Votoplam, partnered with Novartis, is in the global Phase 3 INVEST-HD study for Huntington's disease after positive 24-month PIVOT-HD extension data in 2026. A splicing-platform approach across Huntington's and other CNS targets gives PTC optionality beyond its commercial products, though these are multi-year, binary readouts.
4. Path toward profitability
Rising product revenue narrowed losses sharply, with Q1 2026 EPS of about -$0.03 well ahead of expectations. If Sephience scales as guided while legacy costs are managed, PTC has a credible path to sustained operating profitability, a milestone that would rerate a still-unprofitable specialty pharma.
What are the risks to PTC Therapeutics, Inc. (PTCT)?
The largest risk is legacy-franchise erosion: Translarna is sold in Europe without a valid marketing authorization and faces removal, while Emflaza has lost exclusivity, so a meaningful revenue base could disappear. The balance sheet is stretched, with a large liability for sold future royalties, outstanding debt, and a stockholders' deficit, which limits financial flexibility. Pipeline outcomes such as votoplam in Huntington's and vatiquinone are binary and can move the stock sharply, and the FDA has already demanded additional studies that create delays. Competition in SMA and Duchenne from larger players (Roche, Biogen, Novartis, Sarepta) and pricing/reimbursement pressure in rare disease add further uncertainty.
How is PTC Therapeutics, Inc. (PTCT) valued? (approximate, July 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see PTC Therapeutics, Inc.'s investor relations page or your broker.
- Market cap: ~$6.5 billion
- Revenue (TTM): ~$1.0 billion
- 2026 total revenue guidance: ~$1.08-$1.18 billion
- 2026 product revenue guidance: ~$750-$850 million
- Cash & marketable securities: ~$1.9 billion
- Q1 2026 EPS: ~-$0.03
PTCT trades at a mid-single-digit multiple of revenue, typical for a rare-disease specialist still working toward consistent GAAP profitability. Because much of the near-term growth rides on the Sephience launch curve, the valuation is sensitive to launch trajectory and legacy-revenue durability rather than a simple earnings multiple. The heavy royalty-monetization liabilities mean enterprise value differs materially from market cap.
Who competes with PTC Therapeutics, Inc. (PTCT)?
Rare neuromuscular and SMA players
Roche/Genentech (Evrysdi), Biogen (Spinraza), Novartis (Zolgensma/Itvisma), and Sarepta (Elevidys and exon-skippers) compete across SMA and Duchenne, the disease areas where PTC's Evrysdi royalty and Translarna/Emflaza franchises sit.
Metabolic and PKU competition
In PKU, Sephience competes with BioMarin's established Kuvan and Palynziq, so PTC must win share in a market with entrenched incumbents and differing patient populations.
Rare-disease and CNS biotech peers
Broader rare-disease and neurology developers such as Ultragenyx, Alnylam, and uniQure represent peer competition for capital, talent, and pipeline assets like the votoplam Huntington's program.
How to invest in PTC Therapeutics, Inc. (PTCT)
There are three common ways to get PTCT exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so PTCT sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where PTCT fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on PTC Therapeutics, Inc. (PTCT)
PTCT is a real, revenue-generating rare-disease specialist in transition, where the Sephience launch and the votoplam Huntington's program carry the upside against genuine legacy-revenue and regulatory risk.
More on PTC Therapeutics, Inc. (PTCT)
Whether PTCT is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is PTCT a buy?, and where the stock could go from here in the PTCT stock forecast.
For income investors, whether PTCT pays a dividend and how the payout looks is covered in does PTCT pay a dividend?
Build a basket around PTCT with Walnut
Use PTC Therapeutics, Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What does PTC Therapeutics do?
+
PTC Therapeutics is a commercial-stage biopharmaceutical company that develops and sells medicines for rare and neurological diseases, including PKU, Duchenne muscular dystrophy, and AADC deficiency, and it earns royalties on the SMA drug Evrysdi.
Is PTCT profitable?
+
PTC is not yet consistently profitable on a GAAP basis, but rising product revenue narrowed its losses sharply, with Q1 2026 EPS of about -$0.03 versus much larger expected losses. Sustained profitability depends on how far the Sephience launch scales.
What is Sephience and why does it matter?
+
Sephience (sepiapterin) is PTC's treatment for phenylketonuria (PKU). It is the company's fastest-growing product, contributing roughly $125 million in Q1 2026, and it is the primary reason management raised 2026 revenue guidance.
What are PTCT's biggest risks?
+
Key risks include erosion of legacy drugs (Translarna's European authorization issues and Emflaza's lost exclusivity), a stretched balance sheet with large royalty-sale liabilities, binary pipeline readouts, FDA-required additional studies, and strong competition in SMA and Duchenne.
How does PTCT make money from Evrysdi?
+
PTC helped discover Evrysdi (risdiplam), which Roche/Genentech markets for spinal muscular atrophy, and it collects royalties on those sales. PTC has monetized part of this royalty stream to raise cash, trading future income for near-term liquidity.
What is votoplam?
+
Votoplam is PTC's splicing-modifier drug candidate, partnered with Novartis, being tested in the Phase 3 INVEST-HD trial for Huntington's disease after positive extension-study data in 2026. It is a key long-term pipeline catalyst.
How large is PTC Therapeutics?
+
PTC has a market capitalization of roughly $6.5 billion and trailing revenue near $1 billion, with 2026 total revenue guidance of about $1.08 to $1.18 billion, placing it among mid-cap rare-disease biopharma companies.
How can someone invest in PTCT?
+
PTCT trades on the Nasdaq and can be bought through any standard brokerage account. Because it is a single volatile biotech with launch and pipeline dependencies, some investors weigh it as one holding within a diversified healthcare or rare-disease allocation. Walnut is not an investment adviser.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with PTC Therapeutics, Inc.'s investor relations page or your broker before making investment decisions.